MCRB Seres Therapeutics

Seres Therapeutics to Participate in Cantor 2024 Global Healthcare Conference

Seres Therapeutics to Participate in Cantor 2024 Global Healthcare Conference

CAMBRIDGE, Mass., Sept. 13, 2024 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that the Company, will participate in the Cantor Global Healthcare Conference and Eric Shaff, President and Chief Executive Officer, will represent Seres in a presentation on September 18, 2024 at 3:05 p.m. ET.

A video webcast of the presentation will be available under the “Events and Presentations” tab on the “Investors and News” section of Seres’ website. The replay will become available approximately one hour after the event and will be archived for 21 days.

About Seres Therapeutics

Seres Therapeutics, Inc. (Nasdaq: MCRB) is a commercial-stage company focused on improving patient outcomes in medically vulnerable populations through novel live biotherapeutics. Seres led the successful development and approval of VOWST™, the first FDA-approved orally administered microbiome therapeutic. The Company is developing SER-155, designed to prevent gastrointestinal-derived bloodstream infections, enhance epithelial barrier integrity, and induce immune tolerance responses to reduce the incidence of graft-versus-host-disease. The Company is also advancing additional cultivated oral live biotherapeutics for medically vulnerable populations, including those with chronic liver disease, cancer neutropenia, and solid organ transplants. For more information, please visit .

Investor and Media Contacts:

Carlo Tanzi, Ph.D.

Kendall Investor Relations



EN
13/09/2024

Underlying

MCRBSeres Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Seres Therapeutics

 PRESS RELEASE
Free
MCRB Seres Therapeut...

Seres Therapeutics to Announce First Quarter 2025 Financial Results an...

Seres Therapeutics to Announce First Quarter 2025 Financial Results and Business Updates on May 7, 2025 CAMBRIDGE, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will host a conference call and live audio webcast on May 7, 2025 at 8:30 a.m. ET to discuss first quarter 2025 financial results and provide business updates. To access the conference call, please dial 800-715-9871 (domestic) or 646-307-1963 (international) and reference the conference ID number 4618787. To join the l...

April 23, 2025 1 EN
 PRESS RELEASE
Free
MCRB Seres Therapeut...

Seres Therapeutics Reports Fourth Quarter and Full Year 2024 Financial...

Seres Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates Recent FDA feedback received on SER-155 allogeneic hematopoietic stem cell transplant (allo-HSCT) next study provides support for the proposed primary efficacy endpoint of reduction in bloodstream infections (BSIs) at day 30 post-HSCT; Company expects to submit draft study protocol to FDA in Q2 2025 SER-155 Phase 1b placebo-controlled study exploratory translational biomarker data reinforce intended mechanisms of action, are consistent with clinical results that showed a significa...

March 13, 2025 1 EN
 PRESS RELEASE
Free
MCRB Seres Therapeut...

Seres Therapeutics to Announce Fourth Quarter and Full Year 2024 Finan...

Seres Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Business Updates on March 13, 2025 CAMBRIDGE, Mass., March 04, 2025 (GLOBE NEWSWIRE) --  Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will host a conference call and live audio webcast on March 13, 2025 at 8:30 a.m. ET to discuss fourth quarter and full year 2024 financial results and provide business updates. To access the conference call, please dial 800-715-9871 (domestic) or 646-307-1963 (international) and reference the co...

March 4, 2025 1 EN
 PRESS RELEASE
Free
MCRB Seres Therapeut...

Seres Therapeutics Receives Feedback From FDA on SER-155 Allogeneic He...

Seres Therapeutics Receives Feedback From FDA on SER-155 Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT) Development Approach FDA has provided input on key elements of the SER-155 allo-HSCT clinical development plans including support for the proposed primary efficacy endpoint of reduction in bloodstream infections (BSIs) as of 30 days post HSCT in the next study Seres has submitted clarification questions to FDA and expects a response in the coming weeks, which will inform the proposed protocol for the next SER-155 study in allo-HSCT, which the Company anticipates submitting to ...

March 3, 2025 1 EN
 PRESS RELEASE
Free
MCRB Seres Therapeut...

Seres Therapeutics Announces Receipt of Expected $50 Million Installme...

Seres Therapeutics Announces Receipt of Expected $50 Million Installment Payment Related to VOWST Sale CAMBRIDGE, Mass., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB) (Seres or the Company), a leading live biotherapeutics company, announced today the receipt of a $50 million installment payment related to the Company’s previously announced sale of its VOWST business to Société des Produits Nestlé S.A (SPN, and with certain of its affiliates, collectively, Nestlé Health Science). This installment payment was expected as Seres is fulfilling its transition obligat...

January 16, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch